Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2012

Open Access 01.12.2012 | Case report

A late recurring and easily forgotten tumor: ovarian granulosa cell tumor

verfasst von: Yi-Chan Chen, Liang-Che Chang, Ruey-Shyang Soong

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2012

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Ovarian granulosa cell tumor (GCT) is a malignant tumor with slow progression. The recurrence of granulosa cell tumor often happens after 5 years, leading to a ‘forgotten tumor’ by the patient. We present the case of a 64-year-old woman with a presentation of left flank pain. An initial computed tomography scan revealed a single tumor with multiple adjacent organ invasions. Surgical intervention was prescribed and the pathological results revealed a metastatic granulosa cell tumor. We also review the literature for the follow-up and further management of this tumor.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7819-10-85) contains supplementary material, which is available to authorized users.

Introduction

Ovarian granulosa cell tumor (GCT) is a malignant tumor originating from the sex-cord stromal cells of the ovary. It is an uncommon primary malignant tumor of the ovary and represents 2% to 5% of all ovarian cancers [1]. This tumor is classified into juvenile GCT and adult GCT, and the majority of the cases are the adult type. GCT occurs at any age but there are two peaks in occurrence: at reproductive age and postmenopausal age [2]. The incidence of GCT in women in Western countries is twice that of women in Asia countries [3]. The clinical symptoms of GCT are abdominal pain and abnormal vaginal bleeding, and some cases may also present with menorrhagia, irregular menstruation, or amenorrhea in the reproductive age group. GCT is a cancer with long natural history, and recurrence often happens after 5 years of follow-up [1]. Most cases are diagnosed at stage I disease, therefore such patients need long-term follow-up.

Case report

We present the case of a 64-year-old woman who visited our emergency ward due to left flank pain for 1 day. She had a history of hysterectomy and bilateral salpingo-oophorectomy 22 years ago, but could not remember the etiology of the primary disease due to the long time period and being lost to follow-up after the surgery. The pain was located on her left flank with radiation to the left lower quadrant of abdomen. The pain was dull in characteristic without aggravating factors. A physical examination revealed a 10 × 10 cm mass on the left upper quadrant of her abdomen without local tenderness.
An 11.6 × 10.7 mass in the perirenal area was identified on ultrasonography. Abdominal computer tomography (CT) showed a single tumor measuring 10 × 10 cm in the perirenal space (Figure 1). The tumor was hypervascular on the arterial phase with possible gastric high body, spleen, and pancreatic tail invasion. The differential diagnosis was metastatic tumor with unknown origin and gastrointestinal stromal tumor of gastric origin. Maximal debulking surgery was performed including a splenectomy, distal pancreatecomy, partial left adrenectomy and partial excision of the diaphragm.
The gross findings of the tumor are shown in Figure 2. It was well encapsulated and yellowish in color. It was friable with multiple areas of hemorrhage and necrosis. The microscopic findings from a section of the tumor (Figure 3) showed small round to oval tumor cells with multiple distributive patterns, including macrofollicular, microfollicular, diffuse and trabecullar patterns. The tumor cells also showed scanty cytoplasm with a coffee-bean-like nucleus. An immunohistochemical (IHC) stain (Figure 4) was also performed to confirm diagnosis and the IHC stain was positive for CD99, α-inhibin and calretinin, and negative for epithelial membrane antigen (EMA). From the hematoxylin and eosin stain and the IHC stain results, the diagnosis of metastatic GCT was confirmed.

Discussion

GCT is an uncommon malignant tumor of the sex cord/stromal tumor of the ovary. They only represent 2% to 5% of ovarian cancers but patients with GCT need long-term follow-up due to the slow growth of the tumor and long natural history of the tumor [1]. Recurrence of the tumor usually occurs almost 5 years after first treatment and the longest time of recurrence after treatment was 37 years [4]. The recurrence of our patient happened 22 years after the first treatment. Due to the long period of time point and forgotten history from the patient, the diagnosis of tumor recurrence was difficult to confirm before the surgery. The radiological findings of the GCT vary from solid mass to the cystic lesion and some may also present hemorrhage. The two most common classifications are multiseparated cystic mass and unlobulated solid mass with cystic portions [5].
The treatments for GCT include surgical management combined with further chemotherapy and radiation therapy. Because of the few cases, the surgical management is based on the treatment of other ovarian cancer. Although total abdominal hysterectomy and bilateral salpingo-oophorectomy is the standard treatment, for patients who desire pregnancy, unilateral salpingo-oophorectomy can be performed if the disease is only confined to one ovary. For patients with recurrent tumor, aggressive debulking surgery should be performed [6].
Adjuvant chemotherapy for GCT plays a beneficial role. Like other ovarian cancers, platinum-based and taxane-based chemotherapy should be considered first after surgical resection. Although patients with stage I GCT have an excellent prognosis and may not need chemotherapy, patients with a large tumor size, high-grade mytosis index and/or ruptured tumor are recommended for the chemotherapy [7]. For patients with recurrent GCT, chemotherapy should be prescribed to obtain better tumor control and long survival rate. Pectasides et al. reported combination chemotherapy with cisplatin, adriamycin and cyclophosphamide (CAP) for recurrent or advanced GCT. Five complete responses and one partial response were obtained [8].
Radiation therapy is also recommended for recurrent GCT, especially for patients with residual tumor after surgery. Based on the limited recurrent tumor or metastatic cases, some small series of intense radiation therapy for GCT have been reported to offer prolonged survival. Wolf et al. reported 14 patients with measurable GCT receiving radiation therapy after surgery. Complete response was observed in 6 of 14 patients (43%). Three of them relapsed 4 to 5 years later and the other three remain alive without recurrence for 10 to 21 years [9].
Hormonal therapy is also a treatment choice for recurrent GCT. Hardy et al. reported a review of the pathology for 22 GCT cases; all of the tumors were progesterone receptor related and 32% of them were estrogen receptor related. Several case reports also demonstrate treatment with hormonal therapy for recurrent GCT with complete or partial response [10].

Conclusions

GCT has a low malignancy potential and long recurrence period. Patients with this disease at stage I usually do not need chemotherapy after surgery. Therefore, it would be an easily forgotten stromal cell tumor of the ovary if the patient is not regularly followed up. Patients with GCT require long-term follow-up since recurrence usually happens 5 years after first treatment [1]. The symptoms and signs are not specific for the diagnosis of recurrence. Estradiol and inhibin would be elevated before the recurrence of the GCT and can be used as markers during follow-up. Mullerian inhibitory substance (MIS) is still under investigation, but it could be a useful tumor marker of GCT activity [8]. However, because of the forgotten history by the patient and bizarre image findings, it usually leads to difficulty for clinicians to make an accurate diagnosis before surgical intervention. There is still no standard treatment for recurrent GCT, and maximal debulking is still the best strategy. Adjuvant radiation therapy and chemotherapy are still suggested, since benefits with regard to survival are reported. Radiation therapy should also be considered for the local control of possible microresidual tumors.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Anhänge

Authors’ original submitted files for images

Literatur
1.
Zurück zum Zitat Fox HAK, Langley FA: A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. Cancer. 1975, 35: 231-241. 10.1002/1097-0142(197501)35:1<231::AID-CNCR2820350128>3.0.CO;2-O.CrossRefPubMed Fox HAK, Langley FA: A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. Cancer. 1975, 35: 231-241. 10.1002/1097-0142(197501)35:1<231::AID-CNCR2820350128>3.0.CO;2-O.CrossRefPubMed
2.
Zurück zum Zitat Young RH DG, Scully RE: Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol. 1984, 8: 575-596. 10.1097/00000478-198408000-00002.CrossRefPubMed Young RH DG, Scully RE: Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol. 1984, 8: 575-596. 10.1097/00000478-198408000-00002.CrossRefPubMed
3.
Zurück zum Zitat Ohel GKH, Schenker JG: Granulosa cell tumors in Israel:a study of 172 cases. Gynecol Oncol. 1983, 15: 278-286. 10.1016/0090-8258(83)90083-5.CrossRefPubMed Ohel GKH, Schenker JG: Granulosa cell tumors in Israel:a study of 172 cases. Gynecol Oncol. 1983, 15: 278-286. 10.1016/0090-8258(83)90083-5.CrossRefPubMed
4.
Zurück zum Zitat Hines JF KM, Moore JL, Fine KP, Lage JM, Barnes WA: Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the literature. Gynecol Oncol. 1996, 60: 484-488. 10.1006/gyno.1996.0078.CrossRefPubMed Hines JF KM, Moore JL, Fine KP, Lage JM, Barnes WA: Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the literature. Gynecol Oncol. 1996, 60: 484-488. 10.1006/gyno.1996.0078.CrossRefPubMed
5.
Zurück zum Zitat Kim SH KS: Granulosa cell tumor of the ovary: common findings and unusual appearances on CT and MR. J Comput Assist Tomogr. 2002, 26: 756-761. 10.1097/00004728-200209000-00016.CrossRefPubMed Kim SH KS: Granulosa cell tumor of the ovary: common findings and unusual appearances on CT and MR. J Comput Assist Tomogr. 2002, 26: 756-761. 10.1097/00004728-200209000-00016.CrossRefPubMed
6.
Zurück zum Zitat Schwartz PE SJ: Treatment of ovarian stromal tumors. Am J Obstet Gynecol. 1976, 125: 402-411.PubMed Schwartz PE SJ: Treatment of ovarian stromal tumors. Am J Obstet Gynecol. 1976, 125: 402-411.PubMed
7.
Zurück zum Zitat Pectasides DAN, Athanassiou AE: Cisplatin-containing regimen in advanced or recurrent granulosa cell tumours of the ovary. Ann Oncol. 1992, 3: 316-318.PubMed Pectasides DAN, Athanassiou AE: Cisplatin-containing regimen in advanced or recurrent granulosa cell tumours of the ovary. Ann Oncol. 1992, 3: 316-318.PubMed
8.
Zurück zum Zitat Pectasides DPE, Psyrri A: Granulosa cell tumor of the ovary. Canc Treat Rev. 2008, 34: 1-12.CrossRef Pectasides DPE, Psyrri A: Granulosa cell tumor of the ovary. Canc Treat Rev. 2008, 34: 1-12.CrossRef
9.
Zurück zum Zitat Wolf JK MJ, Eifel PJ, Burke TW, Levenback C, Gershenson DM: Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol. 1999, 73: 35-41. 10.1006/gyno.1998.5287.CrossRefPubMed Wolf JK MJ, Eifel PJ, Burke TW, Levenback C, Gershenson DM: Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol. 1999, 73: 35-41. 10.1006/gyno.1998.5287.CrossRefPubMed
10.
Zurück zum Zitat Hardy RD BJ, Nicely CJ, Reid GC: Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol. 2005, 96: 865-869. 10.1016/j.ygyno.2004.10.042.CrossRefPubMed Hardy RD BJ, Nicely CJ, Reid GC: Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol. 2005, 96: 865-869. 10.1016/j.ygyno.2004.10.042.CrossRefPubMed
Metadaten
Titel
A late recurring and easily forgotten tumor: ovarian granulosa cell tumor
verfasst von
Yi-Chan Chen
Liang-Che Chang
Ruey-Shyang Soong
Publikationsdatum
01.12.2012
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2012
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-85

Weitere Artikel der Ausgabe 1/2012

World Journal of Surgical Oncology 1/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.